Methantheline

Summary

Methantheline (CHEMBL1201264) is an approved small molecule (ATC A03AB07); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03AB07
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 340.4 Da · C21H26NO3+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201264
Name	Methantheline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4097
ATC	A03AB07
Molecular formula	C21H26NO3+
Molecular weight	340.4
InChIKey	GZHFODJQISUKAY-UHFFFAOYSA-N

SMILES: CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13

IUPAC name: diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium

Also known as: Methantheline, Methantheline cation, Methantheline ion, Methanthelinium, SID11112123, METHANTHELINE, methantheline, methanthelinium

Parent form; salt/anhydrous children: CHEMBL1200988

Patent coverage: 833 distinct patent families (3,394 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Prelamin-A/C, Histone-lysine N-methyltransferase 2A, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Voltage-gated inwardly rectifying potassium channel KCNH2, Cytochrome P450 2D6, Cytochrome P450 1A2.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM2	7.9	AC50	12.6	nM	CHEMBL_ACT_25196337
CHRM1	7.54	AC50	28.7	nM	CHEMBL_ACT_25210736
LMNA	5.4	Potency	3981	nM	CHEMBL_ACT_3655549
CYP2D6	5.4	Potency	3981	nM	CHEMBL_ACT_4949826
CYP2D6	5.4	AC50	3981	nM	CHEMBL_ACT_6010884
CYP1A2	5	AC50	10000	nM	CHEMBL_ACT_6068530

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4).

The 2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01429090	PHASE1	COMPLETED	Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).